1839-18-5 | 2-Chloroadenine

Packsize	Purity	Availability	Price	Discounted Price
1g	97%	in stock	$7.00	$5.00
5g	97%	in stock	$15.00	$11.00
10g	97%	in stock	$29.00	$20.00
25g	97%	in stock	$70.00	$49.00
100g	97%	in stock	$279.00	$195.00

Description

• Catalog Number: AB43981
• Chemical Name: 2-Chloroadenine
• CAS Number: 1839-18-5
• Molecular Formula: C5H4ClN5
• Molecular Weight: 169.5718
• MDL Number: MFCD00037925
• SMILES: Clc1nc(N)c2c(n1)nc[nH]2
• NSC Number: 7362

Computed Properties

• Complexity: 154
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• XLogP3: 0.4

Upstream Synthesis Route

2-Chloroadenine, a key compound in chemical synthesis, serves as a versatile building block in various reactions due to its unique chemical properties. As a halogenated adenine derivative, 2-Chloroadenine is pivotal in the creation of nucleoside analogs and pharmaceutical agents. Its ability to undergo nucleophilic substitution reactions allows for the introduction of diverse functional groups, enabling the synthesis of complex molecules with specific biological activities. 2-Chloroadenine is particularly valuable in the development of antiviral and anticancer drugs, where its incorporation into nucleic acids can enhance therapeutic efficacy through targeted interactions at the molecular level. In addition, its reactivity and stability make it a valuable tool in organic chemistry research, facilitating the design and optimization of novel compounds for a wide range of applications.

Literature

• Correlation of the time course of development and decay of tolerance to morphine with alterations in sodium pump protein isoform abundance.

  Biochemical pharmacology 20100401

• Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism.

  Epilepsy research 20080101

• [Synthesis of 2-chloro-2'-deoxyadenosine by microbiological transglycosylation using a recombinant Escherichia coli strain].

  Prikladnaia biokhimiia i mikrobiologiia 20080101

• New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile.

  Purinergic signalling 20070901

• Age-related changes in ischemic tolerance in male and female mouse hearts.

  Journal of molecular and cellular cardiology 20050201

• Application of population pharmacokinetics to cladribine.

  BMC pharmacology 20050101

• Kinetic model of oxidation catalyzed by xanthine oxidase-the final enzyme in degradation of purine nucleosides and nucleotides.

  Nucleosides, nucleotides & nucleic acids 20050101

• Human DNA primase uses Watson-Crick hydrogen bonds to distinguish between correct and incorrect nucleoside triphosphates.

  Biochemistry 20040928

• Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia.

  Cancer letters 20040716

• Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed-phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• Synthesis of base substituted 2-hydroxy-3-(purin-9-yl)-propanoic acids and 4-(purin-9-yl)-3-butenoic acids.

  Nucleosides, nucleotides & nucleic acids 20031201

• Oligonucleotides incorporating 8-aza-7-deazapurines: synthesis and base pairing of nucleosides with nitrogen-8 as a glycosylation position.

  Organic & biomolecular chemistry 20030607

• 3'-deoxyribofuranose derivatives of 1-deaza and 3-deaza-adenosine and their activity as adenosine deaminase inhibitors.

  Nucleosides, nucleotides & nucleic acids 20010101

• Structure-activity relationships for the binding of ligands to xanthine or guanine phosphoribosyl-transferase from Toxoplasma gondii.

  Biochemical pharmacology 19951109